Credit Suisse’s Black Diamond Therapeutics BDTX Stock Holding History

Credit Suisse’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$130K	Hold	25,600	–	–	﹤0.01%	2923
2023 Q4	$71.9K	Buy	25,600 +7,600	+42%	+$17.8K	﹤0.01%	3037
2023 Q3	$51.7K	Buy	+18,000	New	+$66.3K	﹤0.01%	3115
2022 Q3	–	Sell	-12	Closed	–	–	4043
2022 Q2	$0	Buy	+12	New	+$28	﹤0.01%	3936
2022 Q1	–	Sell	-38,518	Closed	-$205K	–	3651
2021 Q4	$205K	Sell	38,518 -12,068	-24%	-$84.3K	﹤0.01%	4261
2021 Q3	$427K	Buy	+50,586	New	+$500K	﹤0.01%	3910
2021 Q2	–	Sell	-9,293	Closed	-$225K	–	4446
2021 Q1	$225K	Sell	9,293 -14,509	-61%	-$391K	﹤0.01%	4087
2020 Q4	$763K	Buy	+23,802	New	+$782K	﹤0.01%	3534

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Credit Suisse's BDTX Position: Q1 2024 in Review

Credit Suisse held its Black Diamond Therapeutics (BDTX) position steady in Q1 2024 at 25,600 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

Credit Suisse first reported a position in BDTX in Q4 2020 and has held it in 8 quarters since. The position peaked at $763K in Q4 2020. 88 funds tracked by Wall St. Rank hold BDTX as of Q1 2024.

Credit Suisse held 25,600 shares of Black Diamond Therapeutics worth $130K as of Q1 2024.
Credit Suisse left its Black Diamond Therapeutics share count unchanged in Q1 2024.
Black Diamond Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2923 holding.
Credit Suisse first reported a position in Black Diamond Therapeutics in Q4 2020 and has held it in 8 quarters since.
Credit Suisse's Black Diamond Therapeutics position peaked at $763K in Q4 2020.
88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.